Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: John R Resseger who wrote (3532)	7/10/2000 7:58:21 AM
From: Marsha Landau	Respond to of 3725

EBCT Outperforms Stress Testing in Detecting Coronary Artery Disease J Am Coll Cardiol 2000;36:32-38,326-340. cardiology.medscape.com

To: John R Resseger who wrote (3532)	7/11/2000 5:43:13 PM
From: TA2K	Read Replies (1) \| Respond to of 3725

TOMORROW INDICATORS WILL SCREAM Just studied the charts, and indeed today appears to clearly be a 'local bottom.' And there was a two- to three-tick overreaction to the downside. A typical frustration blowout. Basically LEMMINGS. It's up from here, all through earnings release time. It'll start slowly --- tomorrow likely to be an 'inside day.' But price will steadily rise. Of particular importance: EB-Endoscopy Approval by the FDA should be hitting the wires any day now. Application was submitted in May, and (according to Imatron on the phone just minutes ago) average time for approval is about 10 weeks, and "as few as 4 weeks." So any day now folks. Now is absolutely the time to buy IMAT. Load up those trucks. Be happy, and stay tuned!!